Episurf Medical AB (STO: EPIS B), a provider of minimally invasive and individualised treatment alternatives for people with painful joint injuries, announced on Friday that Dr Kevin D. Plancher, MD, MPH, of Plancher Orthopaedics & Sport Medicine, New York, has been appointed lead investigator for the company's IDE clinical study, EPIC-Knee: Episealer Knee System IDE Clinical Study.
In his new role as lead investigator, Dr Plancher will serve as a medical advisor to Episurf Medical and the other sites and investigators for any trial-related questions. Dr Plancher will also be one of the surgeons performing surgeries in the clinical trial.
Dr Plancher is a board-certified orthopaedic surgeon and sports medicine expert with extensive experience in treating knee cartilage injuries and an expert in minimally invasive procedures.
Currently, he is a clinical professor in Orthopaedics at Albert Einstein College of Medicine in New York. He is an active member of many prestigious national and international societies and serves on the board of the American Academy of Orthopaedic Surgeons.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer